After a decade of sluggish growth, GSK’s latest financial data indicates a possible shift towards sustained operational improvement, sparking renewed investor interest despite lingering volatility.
For much of the past decade, GSK has looked more like a slow-moving defensive name than a fast-growing pharmaceutical group. Yet the latest figures suggest the company may finally be gathering momentum, with revenue, earnings and shareholder returns all pointing in a better direction. In the original Seeking Alpha analysis, the case for GSK was built around a business that appears to be shifting from stagnation towards firmer growth.
Revenue data from Macrotrends show that the improvement is not just a one-quarter fluke. GSK’s annual sales have trended higher over time, with the company recording 7.44% growth in 2025 versus 2024 and a further 9.12% increase in the 12 months ended 31 March 2026. A separate revenue breakdown from Wall Street Zen also shows year-on-year growth of 6.74%, reinforcing the view that the top line has been moving in the right direction rather than simply bouncing from a weak base.
Profitability has been less even, but the recent direction is encouraging. Macrotrends’ net income figures show that GSK’s earnings fell sharply in 2024, declining 42.89% from the previous year, before rebounding by 87.17% in the 12 months ended 31 March 2026. That pattern suggests a company still experiencing volatility, but one that has regained considerable earnings power after a difficult year. Macrotrends also shows that return on equity reached 145.96% in the 12 months ended 30 June 2023, a reminder that GSK’s capital structure and profitability profile can look very different from year to year.
The market has already begun to reflect some of that improvement. CompaniesMarketCap data show GSK delivered a 49.35% return in 2025, after a 9.25% gain in 2023. Even so, longer-run performance remains more modest. AssetsAnalyzer says the stock has produced an average annual return of 3.29% over the past decade, well below the 15.51% average annual return for the S&P 500 over the same period. That gap helps explain why GSK can still look inexpensive or overlooked to some investors, even after its more recent rebound.
For long-term shareholders, the key question is whether this is the start of a sustained rerating or just a better patch after years of frustration. The evidence from the revenue and earnings data points to real operational improvement, but the share price history suggests investors will likely want to see more consistency before awarding GSK a higher valuation for the long haul.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
